We are live on ! Find out more
PBAXU

Phoenix Biotech Acquisition Corp. Unit
PBAXU

Delisted

PBAXU was delisted on the 7th of February, 2024.

Back to rankings

26 hedge funds and large institutions have $29.1M invested in Phoenix Biotech Acquisition Corp. Unit in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% less funds holding

Funds holding: 28 → 26 (-2)

11% less capital invested

Capital invested by funds: $32.6M → $29.1M (-$3.5M)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

67% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 6

Holders
26
Holders Change
-2
Holders Change %
-7.14%
% of All Funds
0.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
6
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CSS
Cubist Systematic Strategies
Connecticut
+$235K
2
WAM
Wolverine Asset Management
Illinois
+$126K
3
UBS Group
UBS Group
Switzerland
+$1.16K

Top Sellers

Rank Fund Capital Flow
1
MP
Mangrove Partners
Connecticut
-$2.01M
2
SRCM
Sage Rock Capital Management
New York
-$1.85M
3
MF
Magnetar Financial
Illinois
-$679K
4
WC
Wealthspring Capital
New York
-$494K
5
SMA
Sage Mountain Advisors
Georgia
-$107K

PBAXU Hedge Fund Activity: Q2 2022 in Review

26 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Phoenix Biotech Acquisition Corp. Unit (PBAXU) for Q2 2022, worth a combined $29.1M — down 11% from $32.6M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of PBAXU and 1 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 2 added.

The largest buyer was Cubist Systematic Strategies, opening a new position worth an estimated $235K. The largest seller was Mangrove Partners, exiting entirely with an estimated $2.01M sold.

  • 26 institutional investors held Phoenix Biotech Acquisition Corp. Unit (PBAXU) as of Q2 2022, down from 28 in Q1 2022.
  • Funds reported $29.1M of Phoenix Biotech Acquisition Corp. Unit stock for Q2 2022, down 11% quarter-over-quarter.
  • 1 fund opened new Phoenix Biotech Acquisition Corp. Unit positions in Q2 2022 and 3 closed out, a net change of -2 holders.
  • The largest Phoenix Biotech Acquisition Corp. Unit buyer in Q2 2022 was Cubist Systematic Strategies, an estimated $235K added.
  • The largest Phoenix Biotech Acquisition Corp. Unit seller in Q2 2022 was Mangrove Partners, an estimated $2.01M sold.

Based on aggregated 13F filings for Q2 2022.